MedPath

江苏正大丰海制药有限公司

Ownership
-
Established
1980-01-05
Employees
-
Market Cap
-
Website
www.ctfh.com.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

129

NMPA:129

Drug Approvals

Polaprezinc Granules

Product Name
聚普瑞锌颗粒
Approval Number
国药准字H20253401
Approval Date
Feb 20, 2025
NMPA

Posaconazole Injection

Product Name
泊沙康唑注射液
Approval Number
国药准字H20249168
Approval Date
Oct 22, 2024
NMPA

Urapidil Hydrochloride Injection

Product Name
盐酸乌拉地尔注射液
Approval Number
国药准字H20249052
Approval Date
Oct 16, 2024
NMPA

Esmolol Hydrochloride Injection

Product Name
盐酸艾司洛尔注射液
Approval Number
国药准字H20244395
Approval Date
Jul 9, 2024
NMPA

Fudosteine Tablets

Product Name
福多司坦片
Approval Number
国药准字H20090216
Approval Date
Feb 8, 2024
NMPA

Linezolid and Glucose Injection

Product Name
利奈唑胺葡萄糖注射液
Approval Number
国药准字H20183528
Approval Date
Dec 18, 2023
NMPA

Atomoxetine Hydrochloride Oral Solution

Product Name
盐酸托莫西汀口服溶液
Approval Number
国药准字H20234564
Approval Date
Nov 28, 2023
NMPA

Linezolid and Glucose Injection

Product Name
利奈唑胺葡萄糖注射液
Approval Number
国药准字H20183529
Approval Date
Nov 22, 2023
NMPA

Calcium Gluconate and Sodium Chloride Injection

Product Name
葡萄糖酸钙氯化钠注射液
Approval Number
国药准字H20234337
Approval Date
Oct 18, 2023
NMPA

Fudosteine oral solution

Product Name
福多司坦口服溶液
Approval Number
国药准字H20234185
Approval Date
Sep 19, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 13
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.